The Effect of Latanoprost on Choroidal Vascularity Index in Glaucoma and Ocular Hypertension

Précis: The choroidal vascularity index (CVI) is a new marker for the choroid. The decrease in CVI following latanoprost use can provide a better understanding of the pathogenesis of the posterior segment side effects of latanoprost such as cystoid macular edema and central serous choroidopathy. Purpose: The purpose of this paper is to evaluate the changes in the CVI, total choroidal area (TCA), stromal area (SA), luminal area (LA), and choroidal thickness (CT) following latanoprost therapy in patients with primary open angle glaucoma and ocular hypertension. Materials and Methods: Patients with newly diagnosed primary open angle glaucoma or ocular hypertension who had never received antiglaucoma therapy were included. Each patient received latanoprost 0.005% once daily. Enhanced depth imaging mode of spectral-domain optical coherence tomography scans was taken before the start of latanoprost therapy and in the first and third months. Subfoveal CT, CVI, TCA, LA, and SA for the submacular area, and 4 quadrants of the peripapillary area were calculated from the scans. Results: A total of 36 eyes of 18 patients were analyzed. Subfoveal CT increased significantly (P=0.007). Mean TCA (P=0.008) and SA (P
Source: Journal of Glaucoma - Category: Opthalmology Tags: Novel Glaucoma Insights: Original Studies Source Type: research